Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Bilwin 20 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Bilwin 20

Approved

STANDARD

Bilwin 20

Stallion Laboratories Pvt. Ltd.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 76d3c29d909dff69
Company: Stallion Laboratories Pvt. Ltd.
Type: Standard

Approval Details

Approval Id: 76d3c29d909dff69
Drug Approval Philippines Name: Bilwin 20
Product Name: Bilwin 20
Registration Number: DRP-14872
Brand Name: Bilwin 20
Generic Name: Bilastine
Dosage Form: Tablet
Dosage Strength: 20 mg
Manufacturer: Stallion Laboratories Pvt. Ltd.
Importer: Ambica International Corporation
Distributor: Ambica International Corporation
Issuance Date: 26 January 2024
Expiry Date: 26 January 2029
Pharmacologic Category: Antihistamine
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

76d3c29d909dff69

Type

Standard

Back to Philippines FDA Approvals